Dimmock, N. J., Rainsford, Edward W., Scott, P. D. (Paul D.) and Marriott, Anthony C.. (2008) Influenza virus protecting RNA : an effective prophylactic and therapeutic antiviral. Journal of Virology, Vol.82 (No.17). pp. 8570-8578. ISSN 0022-538X

Preview	PDF WRAP_Dimmmock_-08jvi_cloned_protecting_virus_v4njd.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (192Kb)
Preview	PDF WRAP_Dimmock_08Figures_for_JVI_acm_new_F7.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (186Kb)

Abstract

Another influenza pandemic is inevitable, and new measures to combat this and seasonal influenza are urgently needed. Here we describe a new concept in antivirals based on a defined, naturally occurring defective influenza RNA that has the potential to protect against any influenza A virus in any animal host. This protecting RNA (244 RNA) is incorporated into virions which although non-infectious, deliver the RNA to those cells of the respiratory tract that are naturally targeted by infectious influenza virus. A small intranasal dose of this 244 protecting virus (120 ng) completely protected mice against a simultaneous lethal (10 LD50) challenge with influenza A/WSN (H1N1) virus. 244 virus also protected mice against a strong challenge dose of all other subtypes tested (H2N2, H3N2, H3N8). This prophylactic activity was maintained in the animal for at least 1 week prior to challenge. 244 virus was 10 to 100-fold more active than previously characterised influenza A defective viruses, and the protecting activity was confirmed to reside in the 244 RNA molecule by recovering a protecting virus entirely from cloned cDNA. There was clear therapeutic benefit when protecting 244 virus was administered 24-48 h after lethal challenge, an effect which has not been previously observed with any defective virus. Protecting virus reduced, but did not abolish, replication of challenge virus in mouse lungs during both prophylactic and therapeutic treatments. Protecting virus is a novel antiviral which has the potential to combat influenza infections in humans, particularly when the infecting strain is not known, or is resistant to antiviral drugs.

Item Type:	Journal Article
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Influenza -- Treatment, Influenza A virus, Antiviral agents, RNA viruses
Journal or Publication Title:	Journal of Virology
Publisher:	American Society for Microbiology
ISSN:	0022-538X
Date:	September 2008
Volume:	Vol.82
Number:	No.17
Number of Pages:	9
Page Range:	pp. 8570-8578
Identification Number:	10.1128/JVI.00743-08
Status:	Peer Reviewed
Access rights to Published version:	Restricted or Subscription Access
Funder:	Mercia Spinner
References:	1. Aronsson, F., B. Robertson, H. G. Ljunggren, and K. Kristensson. 2003. Invasion and persistence of the neuroadapted influenza virus A/NWS/33 in the mouse olfactory system. Viral Immunology 16:415-423. 2. Belshe, R. B., K. L. Nichol, S. B. Black, H. Shinefield, J. Cordova, R. Walker, C. Hessel, I. Cho, and P. M. Mendelman. 2004. Safety, efficacy, and effectiveness of live attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clinical Infectious Diseases 39:920-927. 3. Cane, C., and N. J. Dimmock. 1990. Intracellular stability of the gene encoding influenza virus haemagglutinin. Virology 175:385-390. 4. Cane, C., L. McLain, and N. J. Dimmock. 1987. Intracellular stability of the interfering activity of a defective interfering influenza virus in the absence of virus multiplication. Virology 159:259-264. 5. Cox, N. J., and K. Subbarao. 2000. Global epidemiology of influenza: past and present. Annual Review of Medicine 51:407-421. 6. Cox, N. J., and K. Subbarao. 1999. Influenza. The Lancet 354:1277-1282. 7. Dimmock, N. J. 1996. Antiviral activity of defective interfering influenza virus in vivo, p. 421-445. In S. Myint and D. Taylor-Robinson (ed.), Viral and Other Infections of the Respiratory Tract. Chapman and Hall, London. 8. Dimmock, N. J., and A. C. Marriott. 2006. In vivo antiviral activity: defective interfering virus protects better against virulent influenza A virus than avirulent virus. J. Gen. Virol. 87:In press. 9. Doherty, P. C., D. J. Topham, and R. A. Tripp. 1996. Establishment and persistence of virus-specific CD4+ and CD8+ T cell memory. Immunological Reviews 150:23-44. 10. Duhaut, S. D., and N. J. Dimmock. 2003. Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. Journal of Virological Methods 108:75-82. 11. Duhaut, S. D., and N. J. Dimmock. 1998. Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology 248:241-253. 12. Eichelberger, M. C., M. Wang, W. Allan, R. G. Webster, and P. C. Doherty. 1991. Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. Journal of General Virology 72:1695-1698. 13. Hayden, F. G. 2006. Antiviral resistance in influenza viruses - implications for management and pandemic response. New England Journal of Medicine 354:785-788. 14. Holland, J. J. 1990. Generation and replication of defective viral genomes, p. 77-99. In B. N. Fields and D. M. Knipe (ed.), Virology, 2nd ed. Raven Press, New York. 15. Huang, A. S., and D. Baltimore. 1970. Defective viral particles and viral disease processes. Nature (London) 226:325-327. 16. Jennings, P. A., J. T. Finch, G. Winter, and J. S. Robertson. 1983. Does the higher order of the influenza virus ribonucleoprotein guide sequence rearrangements in influenza viral RNA. Cell 34:619-627. 17. Karber, G. 1968. p. 118. In A. J. Rhodes and C. E. van Rooyen (ed.), Textbook of Virology, 5th ed. Williams and Wilkins Co., Baltimore. 18. Lamb, R. A., and R. M. Krug. 1996. Orthomyxoviridae: the viruses and their replication, p. 1353-1395. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd ed, vol. 1. Lippincott-Raven Publishers, Philadelphia. 19. Le, Q. L., M. Kiso, K. Someya, Y. Sakai, N. D. Nguyen, K. L. H. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Isolation of drug-resistant H5N1 virus. Nature (London) 437:1108. 20. Mann, A., A. C. Marriott, S. Balasingam, R. Lambkin, J. S. Oxford, and N. J. Dimmock. 2006. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 24:4290-4296. 21. Mayor, S. 2006. Review says oseltamivir and zanamivir should be kept for epidemics of flu. British Medical Journal 332:196. 22. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, G. Hobom, and Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned DNAs. Proceedings of the National Academy of Sciences of the United States of America 96:9345-9350. 23. Noble, S., and N. J. Dimmock. 1994. Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus. Journal of General Virology 75:3485-3491. 24. Noble, S., L. McLain, and N. J. Dimmock. 2004. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine 22:3018-3025. 25. Noda, T., H. Sagara, A. Yen, A. Takada, H. Kida, R. H. Cheng, and Y. Kawaoka. 2006. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (London) 439:490-492. 26. Park, C. H., K. Matsuda, Y. Sunden, A. Ninomiya, A. Takada, H. Ito, T. Kimura, K. Ochiai, and T. Umemura. 2003. Persistence of viral RNA segments in the central nervous system of mice after recovery from acute influenza A virus infection. Veterinary Microbiology 97:259-268. 27. Russell, C. J., and R. G. Webster. 2005. The genesis of a pandemic influenza virus. Cell 123:368-371. 28. Sekellick, M. J., and P. I. Marcus. 1982. Interferon induction by viruses. VIII Vesicular stomatitis virus: [+/-] DI-011 particles induce interferon in the absence of standard virions. Virology 117:280-285. 29. Shinya, K., M. Ebina, S. Yamada, M. Ono, N. Kasai, and Y. Kawaoka. 2006. Influenza virus receptors in the human airway. Nature (London) 440:435-436. 30. Simon, A. E., M. J. Roossinck, and Z. Havelda. 2004. Plant virus satellite and defective interfering RNAs: new paradigms for a new century. Annual Review of Phytopathology 42:415-437. 31. Strahle, L., D. Garcin, and D. Kolakofsky. 2006. Sendai defective-interfering genomes and the activation of interferon-beta. Virology 351:101-111. 32. Subbarao, K., H. Chen, D. Swayne, L. Mingay, E. Fodor, G. Brownlee, X. Xu, X. Lu, J. Katz, N. Cox, and Y. Matsuoka. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate by plasmid-based reverse genetics. Virology 305:192-200. 33. Sweet, C., and H. Smith. 1980. Pathogenicity of influenza virus. Microbiological Reviews 44:303-330. 34. Taubenberger, J. K., A. H. Reid, R. M. Lourens, R. Wang, G. Jin, and T. G. Fanning. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature (London) 437:889-893. 35. Wang, M., and R. G. Webster. 1990. Lack of persistence of influenza virus genetic information in ducks. Archives of Virology 111:263-267. 36. Wang, X.-H., R. Aliyari, W.-X. Li, H.-W. Li, K. Kim, R. Carthew, P. Atkinson, and S.-W. Ding. 2006. RNA interference directs innate immunity against viruses in adult Drosophila. Science 312:452-454. 37. Webster, R. G., W. J. Bean, O. T. Gorman, T. M. Chambers, and Y. Kawaoka. 1992. Evolution and ecology of influenza A viruses. Microbiological Reviews 56:152- 179.
URI:	http://wrap.warwick.ac.uk/id/eprint/4345

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item